Concepedia

Sabine Stienen

SS

Statistics

Publications

15

Citations

756

H-Index

15

Active since

2016

Affiliations

Amgen (Germany)(Current)

Amgen (United States)

Universitätsklinikum Würzburg

Comprehensive Cancer Center Mainfranken

University Medical Center Hamburg-Eppendorf

Sabine Stienen is an author at Amgen (Germany) specializing in cancer immunotherapy, oncology, and medicine.

Publications per year

2016–2023

15

Publications

15

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 176 citations · Full text

, , +17

Pasotuxizumab, a Bite <sup>®</sup> Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Immunotherapy · 2020 · 144 citations · Full text

, , +17

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option

Hauke Stamm, Felix Klingler, Eva-Maria Grossjohann et al. · Oncogene · 2018 · 107 citations · Full text

, , +17

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich et al. · Journal of Clinical Oncology · 2019 · 58 citations

, , +17

Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM

Frank J. Warnders, Stijn J.H. Waaijer, Martin Pool et al. · Journal of Nuclear Medicine · 2016 · 38 citations · Full text

, , +17

1–5 of 15